Aptevo Therapeutics and Alligator Bioscience Present New Preclinical Data for ALG.APV-527 at the Society for Immunotherapy of Cancer 2019 Annual Meeting
Aptevo Therapeutics Inc. (APVO)
Last aptevo therapeutics inc. earnings: 8/9 09:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.aptevotherapeutics.com/investor-overview
Company Research
Source: GlobeNewswire
Preclinical Data Show That ALG.APV-527 is Well Tolerated with Repeated Dosing Preliminary in vivo Data Show that ALG.APV-527 has Potent Anti-tumor Activity and Induces an Immunological Memory Response SEATTLE and LUND, Sweden, Nov. 08, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel immuno-oncology and hematology therapeutics and Alligator Bioscience AB (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy today announced that new preclinical data for ALG.APV-527 are being presented at the Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting at the National Harbor, Maryland, November 6-10, 2019. ALG.APV-527 is a novel immunotherapeutic candidate intended for the treatment of a variety of 5T4-positive solid tumors. It is designed to induce signaling through the co-stimulatory receptor 4-1BB (CD137), which is present on activated
Show less
Read more
Impact Snapshot
Event Time:
APVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
APVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
APVO alerts
High impacting Aptevo Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
APVO
News
- Aptevo Therapeutics Inc. (NASDAQ: APVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial [Yahoo! Finance]Yahoo! Finance
- First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor TrialAccesswire
- Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business UpdateAccesswire
- Aptevo Therapeutics Inc. (NASDAQ: APVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
APVO
Sec Filings
- 11/14/24 - Form SC
- 11/8/24 - Form SC
- 11/7/24 - Form 10-Q
- APVO's page on the SEC website